FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

연구/Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache
연구 도서관으로 돌아가기

Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache

November 20, 2026
Share
Emergent 연구

이 주제에 대한 잠재적인 결과가 있지만 추가 검증이 필요합니다. 이러한 발견은 유망하지만 확실하지 않습니다.

이 분석에 대해 알아보기

이 기사는 AI 도구를 사용하여 생성된 요약입니다. 최근 게시된 뉴스 항목이나 임상 시험 목록의 요약으로, 피테이드 연구 커뮤니티에게 빠르고 접근하기 쉬운 개요를 제공하기 위해 작성되었습니다. 정확성을 위해서는 항상 아래 링크로 연결된 원문을 참조하십시오.

Peptide Therapy in Focus: New Study Investigates Amylin's Role in Post-Traumatic Headache

Peptide therapy continues to be a promising avenue for treating complex medical conditions, and recent research is shedding light on its potential impact on post-traumatic headache (PTH). A new study from the Danish Headache Center aims to explore whether pramlintide—a peptide analogue of human amylin—can induce migraine-like symptoms in individuals suffering from PTH following mild traumatic brain injury (mTBI).

Background

Headaches are a common symptom among patients who have experienced mTBI, often persisting long after the initial injury. These persistent headaches can significantly impact quality of life and pose challenges for effective treatment. Pramlintide, an FDA-approved peptide used primarily to manage diabetes by mimicking the effects of human amylin, has shown potential in other neurological conditions due to its vasoactive properties.

Amylin is a hormone that plays a role in glucose regulation but also affects blood vessels and may contribute to headache mechanisms. The Danish Headache Center's study seeks to understand if pramlintide, which closely mimics the structure and function of amylin, could exacerbate or trigger headaches in individuals with PTH. This research aims to provide valuable insights into the underlying causes of these persistent headaches and potentially identify new treatment options.

Key Details

The clinical trial (NCT07340775) is currently recruiting participants who have experienced mTBI within the past year and are suffering from ongoing post-traumatic headache. The study will compare the effects of pramlintide, a synthetic peptide that closely resembles human amylin, with a placebo to determine if there is any correlation between amylin-like peptides and the onset or worsening of migraine symptoms in these patients.

Participants will be carefully monitored for changes in their headache patterns after receiving either pramlintide or a placebo. Researchers hope to gather data on how this peptide influences blood vessel dilation and constriction, which are key factors in migraines and other types of headaches. Understanding these mechanisms could lead to more targeted therapies for individuals struggling with PTH.

Key Takeaways

  • Exploring Amylin's Role: The study aims to investigate the relationship between amylin-like peptides and post-traumatic headache symptoms.
  • Potential New Insights: By comparing pramlintide (a synthetic version of human amylin) with a placebo, researchers hope to uncover new information about the underlying causes of PTH.
  • Implications for Treatment: If pramlintide is found to influence headaches in this population, it could pave the way for innovative treatment approaches using peptide therapy.
  • Patient Participation Needed: The study requires volunteers who have experienced mTBI and ongoing headache symptoms to participate and contribute valuable data.

What This Means

For the peptide research community, this trial represents a significant step towards understanding how specific peptides might influence neurological conditions beyond their primary therapeutic applications. It highlights the potential for cross-disciplinary insights into pain management and neurology through targeted peptide interventions. As more studies like this one continue to explore the diverse roles of peptides in health and disease, we may see an expansion of treatment options that leverage these powerful biological molecules.

---

Source: ClinicalTrials.gov — Published 2026-11-20

This article is for informational purposes only and does not constitute medical advice.

편집자의 주석

이 분석은 AI 도구를 사용하여 생성되었으며 Peptide Contacts 편집팀으로부터 검토되었습니다. 정확성을 위해 항상 원문을 참조하십시오. 원본 출처 전체 세부사항, 방법론 및 데이터는 여기에서 확인하실 수 있습니다.

Peptide Contacts는 정보 제공 목적으로만 피테이드 연구 요약을 큐레이션합니다. 이 내용은 의학적 조언으로 간주되지 않습니다. 건강 결정을 내릴 때 항상 자격 있는 의료 전문가와 상담하십시오.

Comments

Sign in to join the discussion

이 기사는 AI 도구를 사용하여 생성되었으며 정확성을 보장하지 않습니다. 정보 제공 목적으로만 제공되며 의학적 조언으로 간주되지 않습니다. 항상 원문을 참조하고 자격 있는 의료 전문가와 상담하십시오.